These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35289444)

  • 1. Genetic and observational evidence: No independent role for cholesterol efflux over static high-density lipoprotein concentration measures in coronary heart disease risk assessment.
    Kuusisto S; Karjalainen MK; Tillin T; Kangas AJ; Holmes MV; Kähönen M; Lehtimäki T; Viikari J; Perola M; Chaturvedi N; Salomaa V; Raitakari OT; Järvelin MR; Kettunen J; Ala-Korpela M
    J Intern Med; 2022 Jul; 292(1):146-153. PubMed ID: 35289444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variants at the APOE /C1/C2/C4 Locus Modulate Cholesterol Efflux Capacity Independently of High-Density Lipoprotein Cholesterol.
    Low-Kam C; Rhainds D; Lo KS; Barhdadi A; Boulé M; Alem S; Pedneault-Gagnon V; Rhéaume E; Dubé MP; Busseuil D; Hegele RA; Lettre G; Tardif JC
    J Am Heart Assoc; 2018 Aug; 7(16):e009545. PubMed ID: 30369316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholesterol efflux capacity, HDL cholesterol, and risk of coronary heart disease: a nested case-control study in men.
    Cahill LE; Sacks FM; Rimm EB; Jensen MK
    J Lipid Res; 2019 Aug; 60(8):1457-1464. PubMed ID: 31142574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase inhibition.
    Kettunen J; Holmes MV; Allara E; Anufrieva O; Ohukainen P; Oliver-Williams C; Wang Q; Tillin T; Hughes AD; Kähönen M; Lehtimäki T; Viikari J; Raitakari OT; Salomaa V; Järvelin MR; Perola M; Davey Smith G; Chaturvedi N; Danesh J; Di Angelantonio E; Butterworth AS; Ala-Korpela M
    PLoS Biol; 2019 Dec; 17(12):e3000572. PubMed ID: 31860674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel association between CDKAL1 and cholesterol efflux capacity: Replication after GWAS-based discovery.
    Cheon EJ; Cha DH; Cho SK; Noh HM; Park S; Kang SM; Gee HY; Lee SH
    Atherosclerosis; 2018 Jun; 273():21-27. PubMed ID: 29674289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of HDL- and non-HDL-related parameters in cell-cholesterol efflux capacity.
    Asztalos BF; Hauser TH; Goldfine AB; Welty FK; Horvath KV; Schaefer EJ
    Atherosclerosis; 2022 Mar; 345():1-6. PubMed ID: 35183903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KLKB1 and CLSTN2 are associated with HDL-mediated cholesterol efflux capacity in a genome-wide association study.
    Schachtl-Riess JF; Schönherr S; Lamina C; Forer L; Coassin S; Streiter G; Kheirkhah A; Li Y; Meiselbach H; Di Maio S; Eckardt KU; Köttgen A; Kronenberg F;
    Atherosclerosis; 2023 Mar; 368():1-11. PubMed ID: 36812656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDL Cholesterol Metabolism and the Risk of CHD: New Insights from Human Genetics.
    Vitali C; Khetarpal SA; Rader DJ
    Curr Cardiol Rep; 2017 Nov; 19(12):132. PubMed ID: 29103089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Large-Scale Analysis of Determinants, Stability, and Heritability of High-Density Lipoprotein Cholesterol Efflux Capacity.
    Koekemoer AL; Codd V; Masca NGD; Nelson CP; Musameh MD; Kaess BM; Hengstenberg C; Rader DJ; Samani NJ
    Arterioscler Thromb Vasc Biol; 2017 Oct; 37(10):1956-1962. PubMed ID: 28860221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between cholesterol efflux capacity and peripheral artery disease in coronary heart disease patients with and without type 2 diabetes: from the CORDIOPREV study.
    Yubero-Serrano EM; Alcalá-Diaz JF; Gutierrez-Mariscal FM; Arenas-de Larriva AP; Peña-Orihuela PJ; Blanco-Rojo R; Martinez-Botas J; Torres-Peña JD; Perez-Martinez P; Ordovas JM; Delgado-Lista J; Gómez-Coronado D; Lopez-Miranda J
    Cardiovasc Diabetol; 2021 Mar; 20(1):72. PubMed ID: 33766036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct Estimation of HDL-Mediated Cholesterol Efflux Capacity from Serum.
    Kuusisto S; Holmes MV; Ohukainen P; Kangas AJ; Karsikas M; Tiainen M; Perola M; Salomaa V; Kettunen J; Ala-Korpela M
    Clin Chem; 2019 Aug; 65(8):1042-1050. PubMed ID: 30996052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses.
    van Capelleveen JC; Kastelein JJ; Zwinderman AH; van Deventer SJ; Collins HL; Adelman SJ; Round P; Ford J; Rader DJ; Hovingh GK
    J Clin Lipidol; 2016; 10(5):1137-1144.e3. PubMed ID: 27678430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of High-Density Lipoprotein-Cholesterol Versus Apolipoprotein A-I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study.
    van Capelleveen JC; Bochem AE; Boekholdt SM; Mora S; Hoogeveen RC; Ballantyne CM; Ridker PM; Sun W; Barter PJ; Tall AR; Zwinderman AH; Kastelein JJP; Wareham NJ; Khaw KT; Hovingh GK
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28775061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies.
    Joshi PH; Khokhar AA; Massaro JM; Lirette ST; Griswold ME; Martin SS; Blaha MJ; Kulkarni KR; Correa A; D'Agostino RB; Jones SR; Toth PP;
    J Am Heart Assoc; 2016 Apr; 5(5):. PubMed ID: 27130348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients.
    Gille A; D'Andrea D; Tortorici MA; Hartel G; Wright SD
    Arterioscler Thromb Vasc Biol; 2018 Apr; 38(4):953-963. PubMed ID: 29437574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in lipid measures and incident coronary heart disease: Tehran Lipid & Glucose Study.
    Nejat A; Mirbolouk M; Mohebi R; Hasheminia M; Tohidi M; Saadat N; Azizi F; Hadaegh F
    Clin Biochem; 2014 Sep; 47(13-14):1239-44. PubMed ID: 24657509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis).
    Mackey RH; Greenland P; Goff DC; Lloyd-Jones D; Sibley CT; Mora S
    J Am Coll Cardiol; 2012 Aug; 60(6):508-16. PubMed ID: 22796256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDL (High-Density Lipoprotein) Subclasses, Lipid Content, and Function Trajectories Across the Menopause Transition: SWAN-HDL Study.
    El Khoudary ( سمر رياض الخضري ) SR; Chen (陈曦润) X; Nasr ( ألكسس نصر ) AN; Billheimer J; Brooks MM; McConnell D; Orchard TJ; Crawford SL; Matthews KA; Rader DJ
    Arterioscler Thromb Vasc Biol; 2021 Feb; 41(2):951-961. PubMed ID: 33267661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of black race between high density lipoprotein cholesterol content, high density lipoprotein particles and coronary events (from the Dallas Heart Study).
    Chandra A; Neeland IJ; Das SR; Khera A; Turer AT; Ayers CR; McGuire DK; Rohatgi A
    Am J Cardiol; 2015 Apr; 115(7):890-4. PubMed ID: 25661572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk: A community-based cohort study.
    Qi Y; Liu J; Wang W; Wang M; Zhao F; Sun J; Liu J; Zhao D
    J Clin Lipidol; 2018; 12(1):89-98.e2. PubMed ID: 29217413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.